Novaartis Par Faisale Se MNC Straitiji Badlegi

Business »

Novaartis Par Faisale Se MNC Straitiji Badlegi

Mumbai/nai Delhi. . Supreme court ne Swiss pharma company novaartis ko Cancer ke ilaaj ki dava glaaivek ke peteint ki manjoori dene se inkaar kar diya hai. Isse videshi pharma companiyon ko bhaarateeya market mein apni rananeeti badalne par majaboor hona pad sakta hai. Unhein ab lokal companiyon ke saath jyaada se jyaada deal karni pad sakti hai aur davaaon ki oonchi keemat ko neeche laana pad sakta hai. Supreme court ne apne faisale mein kaha hai ki glaaivek Indian peintets act ki dhaara 3(di) ke tahat inakreemeintal inoveshan ka maamala hai aur yah kisi bhi suraksha ki hakdaar naheen hai. Adaalat ne kaha hai ki company peteint act mein nirdhaarit maanadand ko poora karne mein naakaam rahi hai. Is faisale se novaartis ke liye glaaivek ka peteint haasil karne ki koshishon par viraam lag gaya hai. Ab blood Cancer ke ilaaj ki is dava ki keemat desh mein kam hi rahegi. Agar court ka faisala novaartis ke paksh mein jaata to mareejon ko ek maheene ki doj ke liye 1.20 lakh rupae kharch karne padte. Glaaivek ke jenarik vairiyent ke ek maheene ke doj ki keemat 8,000 rupae hai. Faisale ke baad novaartis ke share somvaar ko 6.8 feesadi tak ludhak gaye the. Baad mein company ke share 1.81 feesadi neeche 587.95 rupae par band hue. Faisale ke baad novaartis ne desh ke peteint kaanoon ko kamjor bataate hue iski ninda ki hai. Iske saath hi company ne kaha ki vah Bhaarat mein nivesh ko lekar saavadhaani barategi aur research end development par inavestameint naheen karegi. Novaartis India ke Chairman ranajeet saahani ne kaha, 'Intelekchual prauparti ke liye Bhaarat mein maahaul theek naheen hai. Ham bandha mahasoos kar rahe hain. Novaartis Bhaarat ko lekar pratibaddh hai, lekin yahaan research end development segameint mein koi nivesh naheen hoga. ' malteeneshanal pharma lobby organization of faarmaasyootikl prodyoosars (opeepeeaai) ne bhi is faisale par niraasha jataai hai. Is faisale se global pharma market mein Bhaarat ke alag-thalag padne ki aashanka paida ho gayi hai. Aisa isliye ki haal mein court ke kuchh faisalon ke kaaran pharma emaenasi haashiye par pahunch gayi hain. Haalaanki, eksaparts ki maanein to Bhaarat ke 18,000 karod rupae saalaana ke drag market mein peteint vaale drag ka hissa mahaj 1 feesadi hai. Unke mutaabik, emaenasi peteint vaale prodakts ke mukaabale jenarik ya braanded jenarik davaaen bechakar jyaada paisa kamaati hain. Enjel broking mein vaais presideint (research) sarabajeet Kaur naangara ne bataaya, 'Hamaare hisaab se novaartis se jude faisale ka industry ke daayanemiks par khaas asar naheen hoga. Bhaarat mein drag market mein badi hissedaari jenarik segameint ki hai. Lihaaja, is faisale se Indian market ki growth par asar naheen hoga. ' pichhle kuchh saal mein pharma emaenasi ne desh mein 20 nae peteint vaale drag launch kiye hain. Inmein kai prodakts ko ab tak chunauti naheen mili hai.

Novaartis Par Faisale Se MNC Straitiji Badlegi https://www.angrejinews.com/pic/4179